Hydroxymethylglutaryl-CoA Reductase Inhibitors
"Hydroxymethylglutaryl-CoA Reductase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit HMG-CoA reductases. They have been shown to directly lower cholesterol synthesis.
| Descriptor ID |
D019161
|
| MeSH Number(s) |
D27.505.519.186.071.202.370 D27.505.519.389.370 D27.505.954.557.500.202.370
|
| Concept/Terms |
Hydroxymethylglutaryl-CoA Reductase Inhibitors- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Hydroxymethylglutaryl CoA Reductase Inhibitors
- Inhibitors, Hydroxymethylglutaryl-CoA Reductase
- Reductase Inhibitors, Hydroxymethylglutaryl-CoA
- Inhibitors, HMG-CoA Reductase
- Inhibitors, HMG CoA Reductase
- Reductase Inhibitors, HMG-CoA
- HMG-CoA Reductase Inhibitors
- HMG CoA Reductase Inhibitors
- Statins, HMG-CoA
- HMG-CoA Statins
- Statins, HMG CoA
- Inhibitors, Hydroxymethylglutaryl-CoA
- Hydroxymethylglutaryl-CoA Inhibitors
- Inhibitors, Hydroxymethylglutaryl CoA
- Statins
- Inhibitors, Hydroxymethylglutaryl-Coenzyme A
- Hydroxymethylglutaryl-Coenzyme A Inhibitors
- Inhibitors, Hydroxymethylglutaryl Coenzyme A
|
Below are MeSH descriptors whose meaning is more general than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".
This graph shows the total number of publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in this website by year, and whether "Hydroxymethylglutaryl-CoA Reductase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 2 | 0 | 2 |
| 2004 | 2 | 0 | 2 |
| 2006 | 1 | 1 | 2 |
| 2008 | 5 | 0 | 5 |
| 2009 | 0 | 2 | 2 |
| 2010 | 1 | 2 | 3 |
| 2011 | 1 | 1 | 2 |
| 2012 | 2 | 0 | 2 |
| 2014 | 1 | 1 | 2 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 2 | 3 |
| 2017 | 3 | 0 | 3 |
| 2018 | 5 | 0 | 5 |
| 2019 | 2 | 1 | 3 |
| 2020 | 3 | 0 | 3 |
| 2021 | 4 | 0 | 4 |
| 2022 | 3 | 0 | 3 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in Profiles.
-
Can statin preventative treatment inform geroscience-guided therapeutics? Aging Cell. 2023 Dec; 22(12):e13998.
-
The ASCEND-ND trial: study design and participant characteristics. Nephrol Dial Transplant. 2022 10 19; 37(11):2157-2170.
-
Author Response: Association of Statins With Cerebral Atherosclerosis and Incident Parkinsonism in Older Adults. Neurology. 2022 09 27; 99(13):586.
-
Unmet Need for Further LDL-C Lowering in India despite Statin Therapy: Lipid Association of India Recommendations for the Use of Bempedoic Acid. J Assoc Physicians India. 2022 Sep; 70(9):11-12.
-
Gender Differences in Guideline-Directed Medical Therapy for Cardiovascular Disease Among Young Veterans. J Gen Intern Med. 2022 09; 37(Suppl 3):806-815.
-
Evidence for intensive LDL-C lowering for acute coronary syndrome: Recommendations from the Lipid Association of India. J Clin Lipidol. 2022 May-Jun; 16(3):261-271.
-
Association of Statins With Cerebral Atherosclerosis and Incident Parkinsonism in Older Adults. Neurology. 2022 05 10; 98(19):e1976-e1984.
-
High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better. Mayo Clin Proc. 2021 10; 96(10):2660-2670.
-
Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) guidelines for management of dyslipidemia and cardiovascular disease risk reduction: Putting evidence in context. Prog Cardiovasc Dis. 2021 Sep-Oct; 68:2-6.
-
Effect of Statin Therapy on Cognitive?Decline and Incident Dementia?in Older Adults. J Am Coll Cardiol. 2021 06 29; 77(25):3145-3156.